{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:31:01Z","timestamp":1791873061042,"version":"4.3.4"},"reference-count":33,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Obesity"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>This study examined the change in weight at 6\u2009months of naltrexone\/bupropion (NB), a combination pharmacological therapy for weight management, in real\u2010world practice in Canada. The study was conducted through an observational, retrospective, single\u2010arm chart review of adult patients who attended the Wharton Medical Clinic in Ontario, Canada, between 2018 and 2021. The patients had a body mass index \u226530 or \u226527\u2009kg\/m<jats:sup>2<\/jats:sup> with at least one weight\u2010related comorbidity. They were prescribed NB, titrated from 1 (8\u2009mg\/90\u2009mg) to 4 tablets daily, along with lifestyle modification. Approximately 52% of 468 participants completed 6\u2009months of treatment and 48.7% titrated to the maximum dose of 4 tablets daily. Participants were mainly female, with mean age of 49.5\u2009years and BMI 38.4\u2009kg\/m<jats:sup>2<\/jats:sup>. After 6\u2009months, participants lost a mean of 4.23\u2009kg (95% confidence interval [CI] \u22124.99, \u22123.47) or 4.05% (CI \u22124.77, \u22123.34) of body weight, with 42.5% losing at least 5% of their body weight and 15.5% losing at least 10%. The most frequent adverse events were nausea (5.7%), constipation (5.7%), and headache (2.5%). Participants also experienced decreased appetite (14.7%), decreased cravings (13.9%), decreased hunger (9.4%) and felt full sooner (2.5%), which are changes likely to result in sustained healthy food choices and improved quality of life. The 6\u2010month NB treatment adjunct to lifestyle modification in a real\u2010world population resulted in clinically significant weight loss.<\/jats:p>","DOI":"10.1111\/cob.12724","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T07:19:26Z","timestamp":1733123966000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The real\u2010world relationship between naltrexone\/bupropion treatment and weight loss in Canada: A retrospective chart review"],"prefix":"10.1111","volume":"15","author":[{"given":"Sean","family":"Wharton","sequence":"first","affiliation":[{"name":"Wharton Medical Clinic  Burlington Ontario Canada"},{"name":"Faculty of Health Sciences McMaster University  Hamilton Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Kamran","sequence":"additional","affiliation":[{"name":"Wharton Medical Clinic  Burlington Ontario Canada"},{"name":"Toronto General Hospital University Health Network  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lehana","family":"Thabane","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact McMaster University  Hamilton Ontario Canada"},{"name":"Research Institute of St Joe's Hamilton St Joseph's Healthcare Hamilton  Hamilton Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Yin","sequence":"additional","affiliation":[{"name":"Bausch Health  Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Christensen","sequence":"additional","affiliation":[{"name":"Wharton Medical Clinic  Burlington Ontario Canada"},{"name":"Faculty of Kinesiology &amp; Physical Education University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,12]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41574\u2010019\u20100176\u20108"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.191707"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.24095\/hpcdp.35.7.02"},{"key":"e_1_2_10_5_1","unstructured":"Statistics Canada.Overweight and obese adults 2018.2019. Accessed June 7 2023https:\/\/www150.statcan.gc.ca\/n1\/pub\/82-625-x\/2019001\/article\/00005-eng.htm"},{"key":"e_1_2_10_6_1","unstructured":"TchangBG ArasM KumarRB AronneLJ.Pharmacologic Treatment of Overweight and Obesity in Adults. MDText.com.2021https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK279038\/"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/5372190"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2018.10.005"},{"key":"e_1_2_10_9_1","unstructured":"PedersenSD ManjooP WhartonS.Canadian Adult Obesity Clinical Practice Guidelines: pharmacotherapy for obesity management. Version 2.2022. Accessed July 7 2023https:\/\/obesitycanada.ca\/guidelines\/pharmacotherapy\/"},{"key":"e_1_2_10_10_1","volume-title":"package insert","author":"Xenical (orlistat)","year":"2023"},{"key":"e_1_2_10_11_1","volume-title":"package insert","author":"Victoza (liraglutide)","year":"2022"},{"key":"e_1_2_10_12_1","volume-title":"package insert","author":"Ozempic (semaglutide)","year":"2022"},{"key":"e_1_2_10_13_1","volume-title":"package insert","author":"CONTRAVE (naltrexone\/bupropion)","year":"2023"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.20309"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(10)60888\u20104"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2010.147"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13\u20100234"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15138"},{"key":"e_1_2_10_19_1","unstructured":"BrownJ ClarkeC Johnson StoklossaC SievenpiperJ.Canadian Adult Obesity Clinical Practice Guidelines: medical nutrition therapy in obesity management.2022. Accessed September 3 2024https:\/\/obesitycanada.ca\/wp\u2010content\/uploads\/2022\/10\/Medical\u2010Nutrition\u2010Therapy_22_FINAL.pdf"},{"key":"e_1_2_10_20_1","unstructured":"World Medical Association.WMA Declaration of Helsinki \u2010 ethical principles for medical research involving human subjects.2022. Accessed July 7 2023https:\/\/www.wma.net\/policies\u2010post\/wma\u2010declaration\u2010of\u2010helsinki\u2010ethical\u2010principles\u2010for\u2010medical\u2010research\u2010involving\u2010human\u2010subjects\/"},{"key":"e_1_2_10_21_1","unstructured":"International Ethical Guidelines for Health\u2010related Research Involving Humans Fourth Edition.Geneva. Council for International Organizations of Medical Sciences (CIOMS).2016. Accessed July 7 2023https:\/\/cioms.ch\/"},{"key":"e_1_2_10_22_1","unstructured":"International Society for Pharmacoepidemiology.Guidelines for Good Pharmacoepidemiology Practices (GPP).2015. Accessed July 7 2023https:\/\/www.pharmacoepi.org\/resources\/policies\/guidelines-08027\/"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781119013563"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2017.05.016"},{"key":"e_1_2_10_25_1","unstructured":"SAS.SAS 9.4 and SAS Viya 3.3 Programming Documentation. The MI Procedure.2019. Accessed December 13 2023https:\/\/documentation.sas.com\/doc\/en\/pgmsascdc\/9.4_3.3\/statug\/statug_mi_examples01.htm"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010018\u20100805\u2010y"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/osp4.420"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.orcp.2014.08.007"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.7602"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1831"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3224"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020\u2010023\u201003534\u20100"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15403"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0231229"}],"container-title":["Clinical Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cob.12724","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T05:45:19Z","timestamp":1741931119000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cob.12724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1111\/cob.12724"],"URL":"https:\/\/doi.org\/10.1111\/cob.12724","archive":["Portico"],"relation":{},"ISSN":["1758-8103","1758-8111"],"issn-type":[{"value":"1758-8103","type":"print"},{"value":"1758-8111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"2024-04-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e12724"}}